Deal title

Principal company

Partner company

Total projected at signing (US$M)

Start date

August

Amgen and Organovo to explore the utility of Exvive human liver tissue

Amgen Inc.

Organovo Holdings

Payment Unspecified

8/23/17

Cancer Research UK to develop Eli Lilly's LY-3143921 in an early stage trial for cancer

Cancer Research UK

Eli Lilly and Co.

Unknown

8/23/17

Medikine and Organovo to explore Exvive kidney tissue to study progression and reversal of fibrosis because of its multicellular nature

Medikine Inc.

Organovo Holdings

Payment unspecified

8/23/17

Mylan to commercialize Otsuka's delamanid for MDR-TB in South Africa and India

Otsuka Novel Products GmbH

Mylan Pharmaceuticals Inc.

Payment unspecified

8/24/17

Horus to distribute Alimera's Iluvien for diabetic macular edema in France

Alimera Sciences Inc.

Horus Pharma

Payment unspecified

8/29/17

Saol Therapeutics to acquire Winrho SDF, Hepagam B, and Varizig from Aptevo Therapeutics

Aptevo Therapeutics Inc.

Saol Therapeutics Inc.

$74.50

8/31/17

Astrazeneca and Takeda to develop and commercialize MEDI-1341 for Parkinson's disease worldwide

Astrazeneca plc

Takeda Pharmaceutical Co. Ltd.

$400.00

8/29/17

Camargo to provide regulatory consulting services for Lumosa's LT-1001 against pain in the U.S.

Camargo Pharmaceutical Services

Lumosa Therapeutics Co. Ltd.

Payment unspecified

8/28/17

Megapharm to distribute Emmaus Life Sciences' Endari (L-glutamine oral powder) in Israel and Palestine

Emmaus Medical Inc.

Megapharm Ltd.

Payment unspecified

8/30/17

FarmaUSA to distribute Isodiol's Isoderm for headaches, body and joint pain, and nervous system disorders in Brazil and across South America

Isodiol International Inc.

FarmaUSA

Payment unspecified

8/30/17

Asia Genomics to distribute Nanthealth's GPS Cancer in Southeast Asian countries

Nanthealth Inc.

Asia Genomics Pte. Ltd.

Payment unspecified

8/30/17

Servier and Philogen to discover small-molecule therapeutics for undisclosed indication

Philogen SpA

Servier

Payment unspecified

8/25/17

Megapharm to market Santhera Pharmaceuticals' Raxone against Leber's hereditary optic neuropathy in Israel

Santhera Pharmaceuticals AG

Megapharm Ltd.

Payment unspecified

8/31/17

Labcyte and Sengine to provide functional drug screening for oncology

Sengine Precision Medicine

Labcyte Inc.

Unknown

8/30/17

Dong-A ST and Takeda to sell and market Edarbi in Korea

Takeda Pharmaceutical Co. Ltd.

Dong-A ST Co. Ltd.

Payment unspecified

8/30/17

Variantyx and Fdna to integrate Genomic Intelligence platform with Face2gene technology to facilitate rare disease diagnosis

Variantyx

Fdna Inc.

Payment unspecified

8/30/17

Novartis to license gevokizumab and IP related to IL-1 beta targeting antibodies including canakinumab against cardiovascular diseases

Xoma Corp.

Novartis AG

$31.00

8/25/17

September

Abcellera and GSK to identify the antibodies against an undisclosed membrane protein target using single cell antibody screening platform

Abcellera Biologics Inc.

Glaxosmithkline plc

Payment unspecified

9/12/17

GT Biopharma to use Accu-Break Pharmaceuticals' technology to develop Painbrake for neuropathic pain

Accu-Break Pharmaceuticals Inc.

GT Biopharma Inc.

Payment unspecified

9/11/17

Andarix and Wuxi Fortune to develop and commercialize Tozaride for lung and other cancers in China

Andarix Pharmaceuticals Inc.

Wuxi Fortune Pharmaceutical Co. Ltd.

Payment unspecified

9/6/17

Aplagon and Cadila to develop and commercialize the APAC product for the prevention of blood vessel occlusions

Aplagon OY

Cadila Pharmaceuticals (Sweden) AB

Payment unspecified

9/19/17

Taiho to receive a license option to Arcus' product candidates for cancer in Japan and certain other territories in Asia (excluding China)

Arcus Biosciences Inc.

Taiho Pharmaceutical Co. Ltd.

$310.00

9/19/17

China National Bluestar and Asahi Kasei to form joint ventures for the mPPE business in China

Asahi Kasei Corp.

China National Chemical Corp.

Unknown

9/5/17

Aspen Global to acquire remaining rights for Astrazeneca's anesthetic medicines

Aspen Global Inc.

Astrazeneca plc

$766.00

9/14/17

Axxam and Sanofi to optimize a lead series of small molecules for neurodegeneration

Axxam SpA

Sanofi SA

Payment unspecified

9/5/17

Cardiome to distribute Basilea's ceftobiprole in Europe and Israel

Basilea Pharmaceutica International Ltd.

Cardiome Pharma Corp.

$5.25

9/12/17

Beijing Zhongyuan to distribute Genovis' products in Chinese market

Beijing Zhongyuan Ltd.

Genovis AB

Payment unspecified

9/18/17

Bayer to innovate and accelerate cell line development and antibody discovery using BLI's Beacon platform

Berkeley Lights Inc.

Bayer AG

Payment unspecified

9/12/17

Kamada and BGN to advance the research on mechanism of action of alpha-1 antitrypsin

BGN Technologies

Kamada Ltd.

Payment unspecified

9/6/17

Bioverativ and Bicycle to discover, develop and commercialize therapies for hemophilia and sickle cell disease

Bicycle Therapeutics Ltd.

Bioverativ Inc.

$424.20

9/6/17

U.S. Worldmeds to commercialize Catalent's lofexidine against opioid withdrawal and facilitate completion of opioid discontinuation treatment in the U.S.

Catalent Inc.

US Worldmeds LLC

Payment unspecified

9/5/17

Biontech to license Cellscript's nucleoside-mRNA for use in all in vivo applications for treatment of cancer and other diseases

Cellscript Inc.

Biontech AG

Payment unspecified

9/6/17

CPE Funds and 3SBio to establish a joint venture as contract development and manufacturing platform in North America

CITICPE

3SBio Inc.

Unknown

9/1/17

Eisai and Ono to develop combination therapy of Lenvima and Opdivo against hepatocellular carcinoma

Eisai Co. Ltd.

Ono Pharmaceutical Co. Ltd.

Payment unspecified

9/8/17

Evotec and Abivax to discover and develop novel therapies for multiple viral infectious diseases

Evotec AG

Abivax

Payment unspecified

9/7/17

GGC and Fdna to evaluate GGC's patient data using Fdna's Face2gene

Fdna Inc.

Greenwood Genetic Center Inc.

Payment unspecified

9/6/17

Morphotek and Fujirebio Diagnostics to develop CA125 II assay as a companion diagnostic for farletuzumab against ovarian cancer patients

Fujirebio Diagnostics Inc.

Morphotek Inc.

Payment unspecified

9/5/17

Airway to use Glycotope's Glycoexpress for the production of AT-100 against bronchopulmonary dysplasia worldwide

Glycotope GmbH

Airway Therapeutics LLC

Payment unspecified

9/11/17

GMS and Tenshi to establish a joint venture, GMS Tenshi Holdings, to deliver biosimilars to emerging markets

GMS Holdings

Tenshi Life Sciences Pvt. Ltd.

Unknown

9/8/17

Boehringer Ingelheim and Gubra to develop therapeutic peptides for obesity

Gubra Aps

Boehringer Ingelheim Corp.

$298.09

9/7/17

Undisclosed Japanese company to develop Hanall's new formulation of HL-036 for inflammatory ocular diseases and macular degeneration

Hanall Biopharma Co. Ltd.

Undisclosed

Payment unspecified

9/12/17

Harbour to develop and commercialize Hanall's HL-161 and HL-036 for autoimmune diseases, dry eye and other inflammatory diseases in China

Hanall Biopharma Co. Ltd.

Harbour Biomed

$81.00

9/12/17

Cocrystal Pharma to discover novel chemical leads for multiple therapeutic targets using Hitgen's DNA-encoded library technology platform

Hitgen Ltd.

Cocrystal Pharma Inc.

Payment unspecified

9/5/17

Hitgen to discover novel small molecules for Takeda's multiple target therapeutic areas worldwide

Hitgen Ltd.

Takeda Pharmaceutical Co. Ltd.

Payment unspecified

9/11/17

Allergan to use Lyndra's sustained-release technology to develop ultra-long-acting products for Alzheimer's disease

Lyndra Inc.

Allergan plc

$105.00

9/7/17

Millennium Pharmaceuticals and Noile-Immune to develop new CAR-T cell immunotherapy against solid tumors

Noile-Immune Biotech Inc.

Millennium Pharmaceuticals Ltd.

Payment unspecified

9/4/17

Helsinn Therapeutics to copromote Novartis' Zykadia for cancer in U.S.

Novartis AG

Helsinn Therapeutics Inc.

Payment unspecified

9/5/17

GTH to develop Oncobiologics' ONS-1045 and ONS-3010 in emerging markets excluding China, India and Mexico

Oncobiologics Inc.

GMS Tenshi Holdings Pvt. Ltd.

$7.50

9/8/17

Monopar to develop and commercialize Onxeo's Validive for oral severe mucositis worldwide

Onxeo SA

Monopar Therapeutics LLC

$109.00

9/13/17

Ora to conduct phase II clinical study of Hanall's HL-036 for dry eye disease in U.S.

Ora Inc.

Hanall Biopharma Co. Ltd.

Payment unspecified

9/12/17

Gercor to conduct phase II combination study of OSE's Tedopi with a PD-1 checkpoint inhibitor against pancreatic cancer

OSE Immunotherapeutics

Gercor

Payment unspecified

9/6/17

Fosun Pharma to develop and commercialize Palatin's bremelanotide for female sexual dysfunction in China, Taiwan, Hong Kong and Macau

Palatin Technologies Inc.

Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

$105.00

9/6/17

Phosplatin and Merck to evaluate PT-112 in combination with avelumab for cancer

Phosplatin Therapeutics LLC

Merck KGaA

Payment unspecified

9/9/17

Mei Pharma to develop and commercialize Presage's voruciclib against cancer worldwide

Presage Biosciences

Mei Pharma Inc.

$183.90

9/5/17

Vectura to use Pulmatrix's PUR-0200 to develop VR410 for chronic obstructive pulmonary disease

Pulmatrix Inc.

Vectura Group plc

$1.00

9/6/17

Puretech to license Calix milk derived exosome-based technology to 3P Biotechnologies

Puretech Health plc

3P Biopharmaceuticals

Payment unspecified

9/19/17

Petra and Schrodinger to develop therapeutics for cancer and metabolic diseases

Schrodinger Inc.

Petra Pharma Corp.

Payment unspecified

9/19/17

Avadel to develop and commercialize Serenity's Noctiva for disorders in voiding and control of urination including nocturia in the U.S. and Canada

Serenity Pharmaceuticals

Avadel Pharmaceuticals plc

$290.00

9/1/17

Sphaera Pharma and Q Biomed to develop analog of QBM-001 for pediatric developmental nonverbal disorder

Sphaera Pharma

Q Biomed Inc.

Payment unspecified

9/19/17

Maruishi to develop and commercialize Sumitomo's FAAH inhibitor for nausea and vomiting

Sumitomo Dainippon Pharma Co. Ltd.

Maruishi Pharmaceutical Co. Ltd.

Payment unspecified

9/6/17

Synpromics to conduct research on Solid's gene therapy to develop new treatments for Duchenne muscular dystrophy

Synpromics Ltd.

Solid Biosciences LLC

Payment unspecified

9/20/17

TCL to manufacture galacto oligosaccharides using Optibiotix's LPGOS to reduce cardiovascular risk factors by using in food and OTC products

Tata Chemicals Ltd.

Optibiotix Health plc

Payment unspecified

9/5/17

CVC Capital Partners to purchase Teva's women's health portfolio products

Teva Pharmaceutical Industries Ltd.

CVC Capital Partners

$703.00

9/18/17

Undisclosed joint venture company to acquire Therapure's contract development and manufacturing business and certain rights to plasma products and technology for the Chinese market

Therapure Biopharma Inc.

Undisclosed

$290.00

9/1/17

Alvogen to market Vivus' Qsymia in the Republic of Korea for treatment of chronic weight management or weight-related conditions

Vivus Inc.

Alvogen Inc.

Payment unspecified

9/5/17

Zealand Pharma and Orbit Discovery to identify novel peptide therapeutics against gastrointestinal and metabolic diseases

Zealand Pharma A/S

Orbit Discovery

Payment unspecified

9/7/17


Notes

This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis.